✦ LIBER ✦

Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements

✍ Scribed by Hayes, D. N.; Lucas, A. S.; Tanvetyanon, T.; Krzyzanowska, M. K.; Chung, C. H.; Murphy, B. A.; Gilbert, J.; Mehra, R.; Moore, D. T.; Sheikh, A.; Hoskins, J.; Hayward, M. C.; Zhao, N.; O'Connor, W.; Weck, K. E.; Cohen, R. B.; Cohen, E. E. W.

Book ID: 118035680
Publisher: American Association for Cancer Research
Year: 2012
Tongue: English
Weight: 427 KB
Volume: 18
Category: Article
ISSN: 1078-0432
DOI: 10.1158/1078-0432.ccr-11-0563

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II open-label randomized study t

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

✍ György Bodoky, Constanta Timcheva, David Robert Spigel, Phillip Joseph La Stella 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 640 KB

Erratum to: A phase II open-label random

Erratum to: A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

✍ György Bodoky, Constanta Timcheva, David Robert Spigel, Phillip Joseph La Stella 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 61 KB